A study explored how genes shape a person’s predisposition to alcohol, tobacco, cannabis, and opioid use disorders. The findings published in Nature Mental Health reveal how the brain’s wiring is a critical factor in substance abuse.
The researchers analyzed four substance use disorders (alcohol, tobacco, cannabis, and opioids) using advanced genomic methods. They also assessed related externalizing traits such as Attention-Deficit/Hyperactivity Disorder (ADHD), risk-taking, and initiation of substance use. The methodology helped identify hundreds of genetic variants associated with broad genetic vulnerability and genetic traits tied to particular substances.
Most of the addiction risks for developing a substance use disorder can be attributed to genes that influence how the brain regulates impulses, processes rewards, and assesses consequences, and not from genes that specifically impact substance use disorder.
The researchers analyzed genetic data from previously published genome-wide association studies that included more than 2.2 million individuals. The researchers found that genetic risk operates along two main pathways. One is a “behavioral disinhibition” or pathway involving neural systems for self-control, risk assessment, and reward processing. Another type of pathway included pathways associated with specific substances, such as genes involved in nicotine receptors and alcohol metabolism or nicotine receptors.
The research team also conducted network and drug-target analyses that suggested potential biological systems and medications that could be used for treatment. Many of the genes identified for the broad externalizing pathway were similar to those identified in other psychiatric and substance-related disorders.
The researchers found that modeling addiction together with these other traits enhanced their ability to detect genetic effects without sacrificing the means to see substance-specific signals. Many of the genes linked to broad liability were involved in brain signaling, reward processing, and neural plasticity, while substance-specific genes mapped onto pathways such as alcohol metabolism or nicotinic acetylcholine receptors that are active in tobacco use.
The researchers also used these genomic discoveries to build polygenic scores, summary measures that combine thousands of genetic variants into a single index of genetic liability. Broad externalizing polygenic scores were especially powerful in predicting risk for multiple substance use disorders, while substance-specific scores provided more precise information about vulnerability to specific drugs, such as alcohol or nicotine.
These insights into genetic risk provide a metric that can identify individuals more vulnerable to addiction, and the polygenic scores can indicate who is at higher risk for specific types of substance abuse. The findings can be used to develop more effective targeted prevention or early intervention initiatives.
Sources: Eureka News Alert, Nature Mental Health
